Basilea Pharmaceutica AG/Fr. BSLN
07:00
09:05
11:10
13:15
15:20
1D1W1MYTD1Y5YMAX
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG operates within the biopharmaceutical industry, focusing on the research, development, and commercialization of innovative medicines to meet medical needs in the areas of infectious diseases and oncology. The company's core products include anti-infective treatments such as Cresemba, an antifungal for invasive aspergillosis and mucormycosis, and Zevtera, a broad-spectrum antibiotic for bacterial infections. Founded in 2000 as a spin-off from Roche, the company is headquartered in Basel, Switzerland. Basilea's unique strategic approach involves enhancing its pipeline through collaborations and licensing agreements, which strengthens its position in the niche market of bacterial resistance and other medical areas with high unmet needs. The company has a significant presence in Europe, the United States, and Asia, expanding its commercial footprint globally.
Ticker
Fr. BSLN
Sector
Primary listing
XSWX
Employees
189
Headquarters
Allschwil, Switzerland
Website
BSLN Metrics
BasicAdvanced
CHF 617m
15.96
CHF 3.14
0.41
-
Price and volume
Market cap
CHF 617m
Beta
0.41
52-week high
CHF 59.70
52-week low
CHF 44.70
Average daily volume
27k
Financial strength
Current ratio
5.115
Quick ratio
4.533
Long term debt to equity
68.121
Total debt to equity
69.733
Interest coverage (TTM)
15.56%
Profitability
EBITDA (TTM)
54.063
Gross margin (TTM)
37.51%
Net profit margin (TTM)
17.30%
Operating margin (TTM)
22.20%
Effective tax rate (TTM)
12.28%
Revenue per employee (TTM)
CHF 1,230,000
Management effectiveness
Return on assets (TTM)
11.95%
Return on equity (TTM)
38.48%
Valuation
Price to earnings (TTM)
15.955
Price to revenue (TTM)
2.639
Price to book
4.78
Price to tangible book (TTM)
4.8
Price to free cash flow (TTM)
10.354
Free cash flow yield (TTM)
9.66%
Free cash flow per share (TTM)
4.839
Growth
Revenue change (TTM)
11.43%
Earnings per share change (TTM)
-46.05%
3-year revenue growth (CAGR)
16.29%
10-year revenue growth (CAGR)
15.97%
3-year earnings per share growth (CAGR)
45.47%
10-year earnings per share growth (CAGR)
-6.41%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs